{"id":120006,"date":"2026-09-08T12:34:13","date_gmt":"2026-09-08T12:34:13","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/120006\/"},"modified":"2026-09-08T12:34:13","modified_gmt":"2026-09-08T12:34:13","slug":"astrazenecas-copd-drug-shows-strong-results-in-pivotal-studies","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/120006\/","title":{"rendered":"AstraZeneca\u2019s COPD drug shows strong results in pivotal studies"},"content":{"rendered":"<p class=\"wp-block-paragraph\">In a pair of late-stage trials, a drug from AstraZeneca reduced the dangerous flare-ups that drive the worsening of COPD, positioning it as a potential new option for the vast numbers of patients with the debilitating lung condition, according to data released Tuesday.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Results from the Phase 3 trials of the drug, called tozorakimab, also amount to a re-assuring victory for AstraZeneca, which is known for its metronomic success in trials but has seen some notable misses in recent months, most dramatically with a <a href=\"https:\/\/www.statnews.com\/2026\/08\/28\/astrazeneca-ionis-wainua-eplontersen-attr-cm-study-failure-bridgebio-alnylam\/\" rel=\"nofollow noopener\" target=\"_blank\">heart disease drug<\/a>. Analysts and the company have projected that \u201ctozo,\u201d as the injectable drug is dubbed, could reap billions in annual sales if approved, both in COPD \u2014 which, as the third-leading cause of death globally, remains greatly underserved \u2014 and in other conditions including asthma.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">In the trials, tozo reduced COPD exacerbations \u2014\u00a0any sudden worsening of the disease requiring medical care, whether a severe cough or breathlessness \u2014 by about 30% across all patients over a year, according to data presented at the European Respiratory Society\u2019s annual conference in Barcelona and <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2606998\" target=\"_blank\" rel=\"noopener nofollow\">published<\/a> in the New England Journal of Medicine. That finding makes tozo competitive with other COPD treatments that have reached patients in recent years, but notably, the tozo trials included participants not eligible for the other new drugs. The benefits seen in those patients could give AstraZeneca a large segment of the market to itself.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/05\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"In a pair of late-stage trials, a drug from AstraZeneca reduced the dangerous flare-ups that drive the worsening&hellip;\n","protected":false},"author":2,"featured_media":120007,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,25365,11314,2029,20102],"class_list":["post-120006","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-chronic-disease","tag-drug-development","tag-pharmaceuticals","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117235448865704645","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/120006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=120006"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/120006\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/120007"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=120006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=120006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=120006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}